CD34 and Bcl-2 as predictors for the efficacy of neoadjuvant chemotherapy in cervical cancer.
Bcl-2
CD34
Cervical cancer
Neoadjuvant chemotherapy
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
29
11
2019
accepted:
24
11
2020
pubmed:
5
1
2021
medline:
11
11
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
Successful neoadjuvant chemotherapy (NACT) could improve the surgical resection rate and radical curability of patients with cervical cancer, but only a subset of patients benefits. Therefore, identifying predictive biomarkers are urgently needed. The aim of this study was to evaluate the predictive value of CD34 and Bcl-2 in the NACT effectiveness of cervical cancer. Sixty-seven patients with locally advanced cervical cancer (FIGO stages IB3, IIA2 or IIB) were classified into two groups based on effective (n = 48) and ineffective (n = 19) response to NACT. Immunohistochemistry was employed to identify CD34 and Bcl-2 expression before and after NACT. We analyzed the associations between the pre-NACT expression of these two biomarkers and the response of NACT. The expression of these two biomarkers before and after NACT was also assessed and compared. More patients were CD34 positive expression before NACT in effective group compared to ineffective group (p = 0.005). However, no statistically significant difference in Bcl-2 expression before NACT were found between two groups (p = 0.084). In NACT effective group, the expression of both CD34 and Bcl-2 after NACT are down-regulated (p < 0.001 and p < 0.001, respectively), while there are no statistical differences between the pre- and post-NACT expression of CD34 and Bcl-2 in NACT ineffective group (p = 0.453 and p = 0.317, respectively). The positive CD34 expression before NACT may serve as a predictive biomarker for NACT of cervical cancer, but the pre-NACT expression of Bcl-2 is not an independent predictor. The down-regulated expression of these two indicators after NACT may indicate effective NACT.
Sections du résumé
BACKGROUND
Successful neoadjuvant chemotherapy (NACT) could improve the surgical resection rate and radical curability of patients with cervical cancer, but only a subset of patients benefits. Therefore, identifying predictive biomarkers are urgently needed. The aim of this study was to evaluate the predictive value of CD34 and Bcl-2 in the NACT effectiveness of cervical cancer.
METHODS
Sixty-seven patients with locally advanced cervical cancer (FIGO stages IB3, IIA2 or IIB) were classified into two groups based on effective (n = 48) and ineffective (n = 19) response to NACT. Immunohistochemistry was employed to identify CD34 and Bcl-2 expression before and after NACT. We analyzed the associations between the pre-NACT expression of these two biomarkers and the response of NACT. The expression of these two biomarkers before and after NACT was also assessed and compared.
RESULTS
More patients were CD34 positive expression before NACT in effective group compared to ineffective group (p = 0.005). However, no statistically significant difference in Bcl-2 expression before NACT were found between two groups (p = 0.084). In NACT effective group, the expression of both CD34 and Bcl-2 after NACT are down-regulated (p < 0.001 and p < 0.001, respectively), while there are no statistical differences between the pre- and post-NACT expression of CD34 and Bcl-2 in NACT ineffective group (p = 0.453 and p = 0.317, respectively).
CONCLUSION
The positive CD34 expression before NACT may serve as a predictive biomarker for NACT of cervical cancer, but the pre-NACT expression of Bcl-2 is not an independent predictor. The down-regulated expression of these two indicators after NACT may indicate effective NACT.
Identifiants
pubmed: 33392721
doi: 10.1007/s00404-020-05921-8
pii: 10.1007/s00404-020-05921-8
pmc: PMC8277608
doi:
Substances chimiques
Antigens, CD34
0
Proto-Oncogene Proteins c-bcl-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
495-501Informations de copyright
© 2021. The Author(s).
Références
Bray FI, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 68(6):394–424
doi: 10.3322/caac.21492
Kokka F, Bryant A, Brockbank E, Powell MEB, Oram D (2015) Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Systematic Rev (4)
Landoni F, Sartori E, Maggino T, Zola P, Zanagnolo V, Cosio S, Ferrari F, Piovano E, Gadducci A (2014) Is there a role for postoperative treatment in patients with stage Ib2–IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study. Gynecol Oncol 132(3):611–617
pubmed: 24342439
doi: 10.1016/j.ygyno.2013.12.010
Hosseini S, Behjati F, Rahimi M, Taheri N, Khorshid HRK, Moghaddam FA, Frouzabadi SG, Karimlou M, Sirati F, Keyhani E (2018) Relationship between PIK3CA amplification and P110α and CD34 tissue expression as angiogenesis markers in iranian women with sporadic breast cancer. Iranian J Pathol 13(4):447–453
Bernard U, Patrick N, Michel C, Gérard-Yves P (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Can Res 64(9):2941
doi: 10.1158/0008-5472.CAN-03-1957
Aijaz M, Alam K, Maheshwari V, Hakim S, Kamal M (2019) Clinicopathological study of role of CD34 expressions in the stroma of premalignant and malignant lesions of uterine cervix. Ann Diagn Pathol 38:87–92. https://doi.org/10.1016/j.anndiagpath.2018.11.007
pubmed: 30529837
doi: 10.1016/j.anndiagpath.2018.11.007
Kontos CK, Christodoulou M, Scorilas A (2014) Apoptosis-related BCL2-family Members: Key Players in Chemotherapy. Anticancer Agents Med Chem 14(3):353–374
pubmed: 23848200
doi: 10.2174/18715206113139990091
Turker P, Segersten U, Malmstrom P, Hemdan T (2019) Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy? Scand J Urol Nephrol 53(1):45–50
Zhu T, Xu F, Zhang L, Zhang Y, Yang C, Cheng M, Chen F, Wang K (2017) Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy. Oncotarget 8(60):101087–101094
pubmed: 29254147
pmcid: 5731857
doi: 10.18632/oncotarget.19686
Luengogil G, Gonzalezbillalabeitia E, Chavesbenito A, Martinez EG, Garre EG, Vicente V, La Pena FAD (2015) Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis. Breast Cancer Res Treat 151(3):577–587
doi: 10.1007/s10549-015-3421-4
Tsuchida Y, Therasse P (2001) Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol 37(1):1–3
pubmed: 11466715
doi: 10.1002/mpo.1154
Hu T, Shuang L, Chen Y, Jian S, Xiong L, Huang K, Ru Y, Li W, Chen Z, Yao J (2012) Matched-case comparison of neoadjuvant chemotherapy in patients with FIGO stage IB1-IIB cervical cancer to establish selection criteria. Eur J Cancer 48(15):2353–2360
pubmed: 22503395
doi: 10.1016/j.ejca.2012.03.015
Uegaki K, Shimada M, Sato S, Deura I, Naniwa J, Sato S, Oishi T, Itamochi H, Harada T, Kigawa J (2014) Outcome of stage IB2–IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy. Int J Clin Oncol 19(2):348–353
pubmed: 23592280
doi: 10.1007/s10147-013-0559-0
Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri S, Kerkar R, Tongaonkar HB, Ghosh J, Gulia S (2018) Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol 36(16):1548
pubmed: 29432076
doi: 10.1200/JCO.2017.75.9985
Rydzewska L, Tierney JF, Vale CL, Symonds P (2012) Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database System Rev 12 (1)
Sun H, Huang K, Tang F, Li X, Wang X, Long S, Zhou S, Suolangquzhen ZJ, Ning R (2018) Adjuvant chemotherapy after surgery can improve clinical outcomes for patients with IB2-IIB cervical cancer with neoadjuvant chemotherapy followed by radical surgery. Sci Rep 8(1):6443
pubmed: 29691415
pmcid: 5915525
doi: 10.1038/s41598-018-24413-z
Takatori E, Shoji T, Omi H, Kagabu M, Miura F, Takeuchi S, Kumagai S, Yoshizaki A, Sato A, Sugiyama T (2015) Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy. Int J Clin Oncol 20(2):345–350
pubmed: 24825458
doi: 10.1007/s10147-014-0702-6
Paduch R (2016) The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cellular Oncol 39(5):397–410
doi: 10.1007/s13402-016-0281-9
Bing Z, Yang JR, Jiang YQ, Chen SF (2014) Evaluation of angiogenesis in non-small cell lung carcinoma by CD34 immunohistochemistry. Cell Biochem Biophys 70(1):327–331
pubmed: 24676677
doi: 10.1007/s12013-014-9916-5
Benazzi C, Al-Dissi A, Chau CH, Figg WD, Sarli G, Oliveira JT, De, (2014) Grtner F (2014) Angiogenesis in spontaneous tumors and implications for comparative tumor biology. Scientific World J 21:919570
Sidney LE, Branch MJ, Dunphy SE, Dua HS, Andrew H (2014) Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells 32(6):1380–1389
pubmed: 24497003
pmcid: 4260088
doi: 10.1002/stem.1661
Fathy A, Abdelrahman AE (2018) EZH2, endothelin-1, and CD34 as biomarkers of aggressive cervical squamous cell carcinoma: an immunohistochemical study. Turk Patoloji Dergisi 34 (2)
Gao Z, Wang Q (2015) Curative effect of paclitaxel and cisplatin combined chemotherapy on cervical cancer and its relation with tissue micro vascular and lymphatic vessels density. Pakistan J Pharmac Sci 28 (5 suppl):1849
Pakalniskis MG, Wells WA, Schwab MC, Froehlich HM, Jiang S (2011) Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography:demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer? Radiology 259(2):365
pubmed: 21406632
pmcid: 3079119
doi: 10.1148/radiol.11100699
Tanaka S, Ueno T, Ishiguro H, Morita S, Toi M (2017) The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients
Carrasco J, Gizzi M, Pairet G, Lannoy V, Lefesvre P, J-F G, Hubert C, Jouret-Mourin A, Humblet Y, J-L C (2015) Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. British J Cancer 113(9):1298–1304
doi: 10.1038/bjc.2015.321
Maae E, Steffensen KD, Jakobsen EH, Brandslund I, Sørensen FB, Jakobsen A (2012) Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat 133(1):257–265
pubmed: 22270936
doi: 10.1007/s10549-012-1957-0
Sanusi RS (2019) Outcome of combined neoadjuvant chemotherapy and vitamin a in advanced cervical carcinoma: a randomized double-blind clinical trial. Asian Pacific J Cancer Prev 20(7):2213–2218. https://doi.org/10.31557/APJCP.2019.20.7.2213
doi: 10.31557/APJCP.2019.20.7.2213
Campbell KJ, Tait SWG (2018) Targeting BCL-2 regulated apoptosis in cancer. Open Biol 8(5):180002
pubmed: 29769323
pmcid: 5990650
doi: 10.1098/rsob.180002
Zhou XL, Wang M (2015) Expression levels of survivin, Bcl-2, and KAI1 proteins in cervical cancer and their correlation with metastasis. Genet Mol Res 14(4):17059–17067
pubmed: 26681053
doi: 10.4238/2015.December.16.6
Saito T, Takehara M, Tanaka R, Rong L, Horie M, Wataba K, Ito E, Kudo R (2004) Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma. Gynecol Oncol 92(1):284–292
pubmed: 14751172
doi: 10.1016/j.ygyno.2003.09.027
Jf DMR, Rss DM, Braghiroli MI, Galvão B, Jeb N, Munhoz RR, Guerra J, Nonogaki S, Kimura L, Pfiffer TE (2017) Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer. E Cancer Med Sci 11:767
Moreno-Galindo C, Hermsen M, García-Pedrero JM, Fresno MF, Suárez C, Rodrigo JP (2014) p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. Oral Oncol 50(2):128–134
pubmed: 24239278
doi: 10.1016/j.oraloncology.2013.10.018
Harima Y, Harima K, Shikata N, Oka A, Ohnishi T, Tanaka Y (1998) Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. Gan to Kagaku Ryoho Cancer Chemotherapy 25(9):1273–1277
pubmed: 9703806
Ogura T, Tanaka Y, Tamaki H, Harada M (2016) Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells. Int J Oncol 48(6):2330–2338
pubmed: 27082738
pmcid: 4864052
doi: 10.3892/ijo.2016.3482
Woo JY, Yang SH, Lee YS, Su YL, Kim J, Yong KH (2015) Continuous low-dose temozolomide chemotherapy and microvessel density in recurrent glioblastoma. J Korean Neurosurg Soc 58(5):426–431
pubmed: 26713142
pmcid: 4688311
doi: 10.3340/jkns.2015.58.5.426
Ginés L-G, Enrique G-B, Asunción C-B, Elena GM, Elisa GG, Vicente V, AdlPa F (2015) Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis. Breast Cancer Res Treat 151(3):1–11
Li Y, Zhang Z, Xiao Z, Lin Y, Luo T, Zhou Q, Zhang X (2017) Chemotherapy-mediated miR-29b expression inhibits the invasion and angiogenesis of cervical cancer. Oncotarget 8 (9)